BRAF and melanoma: The U.S. Food and Drug Administration (FDA) has approved trametinib (GSK1120212) for treatment of BRAF-mutant metastatic melanoma [18], and a phase III clinical trial using trametinib in melanomas with BRAFV600E or BRAFV600K mutations showed promising responses [19].